Company Filing History:
Years Active: 2010
Title: Inventor Nigel Charles Barrass: Pioneering Anticancer Innovations
Introduction: Nigel Charles Barrass, an accomplished inventor based in Macclesfield, GB, has made significant contributions to the field of pharmaceuticals. With a focus on anticancer agents, he has secured a patent that holds promise for treating cancer and pain in warm-blooded animals, including humans. His work is critical as the fight against cancer continues to be a major area of medical research and innovation.
Latest Patents: Barrass holds one notable patent titled "N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent." This patent outlines the use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or its pharmaceutically acceptable salt, in the treatment of cancer and pain. His inventive approach targets significant health issues faced by many, highlighting the importance of innovation in medicine.
Career Highlights: Nigel is affiliated with AstraZeneca AB, a leading global biopharmaceutical company. His association with such a reputable organization underscores his expertise and commitment to advancing healthcare solutions. Within AstraZeneca, Barrass has dedicated himself to research that seeks to improve patient outcomes through innovative pharmaceutical developments.
Collaborations: Throughout his career, Barrass has had the opportunity to collaborate with notable colleagues such as David William Tonge and Sian Tomiko Taylor. These collaborations reflect a team-oriented approach in a field where combined expertise often leads to groundbreaking discoveries and advancements in therapeutic options.
Conclusion: In summary, Nigel Charles Barrass exemplifies the spirit of innovation within the pharmaceutical industry. His patent for an anticancer agent demonstrates not only his commitment to combating serious health conditions but also the collaborative nature of research that drives progress. As he continues his work at AstraZeneca AB, the impact of his contributions will likely resonate within the field of medical research for years to come.